ANI Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on ANI Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how ANI Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with ANI Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
ANI Pharmaceuticals Inc (ANI) is a biopharmaceutical company. It focuses on developing, manufacturing, and marketing generic and branded prescription pharmaceuticals. The company also offers over-the-counter (OTC) medicines and pharmaceuticals for rare diseases. ANI also conducts business as a contract development and manufacturing organization (CDMO) that assists in late-stage development to commercial manufacturing of pharmaceutical products, which include tablets and capsules, ointments, creams, liquids, oral suspensions, gels, injections, topical, powder and enema products. The company distributes its products through wholesalers, retail market chains, distributors and mail-order pharmacies, group purchasing organizations, specialty pharmacies and hospitals. ANI is headquartered in Baudette, Minnesota, the US.
Headquarters
United States of America
Address
210 Main Street West, Baudette, Minnesota, 56623
Website
www.anipharmaceuticals.com
Telephone
1 302 6587581
No of Employees
970
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ANIP (NASD)
Revenue (2025)
$883.4M
43.8%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
522.9%
(2025 vs 2024)
Market Cap*
$1.9B
Net Profit Margin (2025)
XYZ
394.7%
(2025 vs 2024)
* As of and is in US$
ANI Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Branded Prescription Pharmaceuticals | Contract Manufacturing and Packaging | Arimidex |
| Generic Prescription Pharmaceuticals | Cortenema | |
| Over The Counter Pharmaceutical: | Cortrophin-Zinc | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | New Products/Services | In March, the company introduced Nitazoxanide Tablets, 500 mg. |
| 2025 | Regulatory Approval | In March, the company announced that the US FDA has approved an expanded label for ILUVIEN (fluocinolone acetonide intravitreal implant) that includes an indication for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). |
| 2024 | New Products/Services | In October, the company introduced a new product known as Estradiol Gel, 0.06%, which is the generic version of the reference listed drug (RLD) EstroGel Gel, 0.06%. |
Competitor Comparison
| Key Parameters | ANI Pharmaceuticals Inc | Amgen Inc | Teva Pharmaceutical Industries Ltd | Viatris Inc | Sun Pharmaceutical Industries Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Israel | United States of America | India |
| City | Baudette | Thousand Oaks | Tel Aviv | Canonsburg | Mumbai |
| State/Province | Minnesota | California | Tel Aviv | Pennsylvania | Maharashtra |
| No. of Employees | 970 | 31,500 | 31,173 | 31,993 | 43,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Patrick D. Walsh | Chairman | Executive Board | 2020 | 65 |
| Nikhil Lalwani | Chief Executive Officer; Director; President | Executive Board | 2020 | 48 |
| Stephen P. Carey | Chief Financial Officer; Senior Vice President - Finance | Senior Management | 2016 | 55 |
| Krista Davis | Chief Human Resources Officer; Senior Vice President | Senior Management | 2022 | 53 |
| Muthusamy Shanmugam | Chief Operating Officer - NJ Operations; Director; Head- Research & Development | Executive Board | 2021 | 58 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer